Social Media Ideas for Fda Approvals

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Datroway]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Ennumo]]>

FDA Approvals in Oncology: April-June 2026 

During the second quarter of 2026, oncology approvals issued by the U.S. Food and Drug Administration expanded the treatment options available for patients with breast cancer, urin...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Xocova]]>

<![CDATA[FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma ]]>

<![CDATA[FDA Sends CRL to Cingulate for CTx-1301]]>

<![CDATA[FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Hepcludex]]>

<![CDATA[FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhi...

<![CDATA[FDA Approves Ennumo to Decrease Incidence of Infection by Febrile Neutropenia ]]>

<![CDATA[FDA Approves Revtorpyk for Treatment of Advanced HR-Positive, HER2-Negative Breast Cancer ]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik]]>

<![CDATA[Ibrance Wins FDA Approval for HR-Positive, HER2-Positive Metastatic Breast Cancer Maintenance Therapy]]>

<![CDATA[FDA Expands Enhertu in Early HER2-Positive Breast Cancer]]>

<![CDATA[FDA Accepts NDA for Giredestrant in ER-Positive Early-Stage Breast Cancer]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Subcutaneous Sarclisa Escena]]>

<![CDATA[FDA Issues CRL to Elevar Therpaeutics for Combination of Rivoceranib and Camrelizumab ]]>

<![CDATA[EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval]]>

<![CDATA[FDA Approves Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy]]>

<![CDATA[FDA Approves Hepcludex as First and Only Approved Treatment for Chronic Hepatitis Delta Virus]]>

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>

<![CDATA[FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry]]>